Table 2.
Characteristics of Patients with Abnormalities on FP Specimen Biopsy.
| Patient | Age in years (Tanner stage) | Procedure | Diagnosis prior to FP | CED of treatment prior to FP (mg/m2) | Risk to fertility of prior treatment | Malignancy present in gonadal biopsy | Germ cells present | Continued long term storage |
|---|---|---|---|---|---|---|---|---|
| 1 | 14 (4) | OTC | Immature teratoma | 0 | 0 | Mixed germ cell tumor | Yes | Yes |
| 2 | 15 (5) | OTC | Desmoplastic Small Round Cell Tumor | 3396 | Minimally increased risk | Desmoplastic Round Cell Tumor | Yes | Yes |
| 3 | 13 (5) | OTC | Rhabdomyosarcoma | 0 | 0 | Rhabdomyosarcoma | Yes | Yes |
| 4 | 4 (1) | OTC | High-Risk Neuroblastoma | 4000 | Minimally increased risk | B Cell Lymphoblastic Leukemia | Yes | Yes |
| 5 | 2 (1) | OTC | Neuroblastoma | 2000 | Minimally increased risk | None | No | Yes |
| 6 | 10 (1) | OTC | B Cell Lymphoblastic Leukemia | 3000 | Minimally increased risk | None | No | Yes |
| 7 | 2 (1) | TTC | B Cell Lymphoblastic Leukemia | 7000 | Significantly increased risk | B Cell Lymphoblastic Leukemia | Yes | Yes |
| 8 | 2 (1) | TTC | B Cell Lymphoblastic Leukemia | 0 | 0 | B Cell Lymphoblastic Leukemia | Yes | Yes |
| 9 | 10 (1) | TTC | Hypergonadotropic Hypogonadism | 0 | 0 | None | No | Yes |
| 10 | 4 (1) | TTC | Aplastic Anemia | 0 | 0 | None | No | Yes |
Patients who either were found to have malignant cells or an absence of germ cells on biopsy of FP tissue are included in this table. Fertility preservation (FP); Cyclophosphamide equivalency dose (CED); Ovarian tissue cryopreservation (OTC); Testicular tissue cryopreservation (TTC).